
Sign up to save your podcasts
Or


As new treatment options become available for IBD patients, it is important to be informed on which treatments will work best for which patient populations. Dr. Adam Ehrlich, Assistant Professor of Medicine at Temple University School of Medicine, joins Rebecca Kaplan to discuss what's coming down the drug pipeline for patients with IBD. He will touch on the recent medication approvals of biologics and biosimilars, as well as how IBD treatments are moving closer to precision medicine.
By ReachMD4.5
1313 ratings
As new treatment options become available for IBD patients, it is important to be informed on which treatments will work best for which patient populations. Dr. Adam Ehrlich, Assistant Professor of Medicine at Temple University School of Medicine, joins Rebecca Kaplan to discuss what's coming down the drug pipeline for patients with IBD. He will touch on the recent medication approvals of biologics and biosimilars, as well as how IBD treatments are moving closer to precision medicine.